Petrelintide (ZP8396)
Definition: An investigational once-weekly long-acting amylin analog from Zealand Pharma being studied for weight management and metabolic disease.
Overview
Petrelintide, formerly known as ZP8396, is Zealand Pharma’s investigational long-acting amylin analog. It is being developed for once-weekly subcutaneous administration as a weight-management therapy. Petrelintide is notable because it is not a GLP-1 receptor agonist; instead, it targets the amylin pathway, a complementary satiety and metabolic hormone system. This makes it a key example of next-generation obesity research beyond GLP-1 monotherapy.
Mechanism of action
Amylin is a pancreatic hormone co-secreted with insulin after meals. Amylin analogs can promote satiety, slow gastric emptying, and influence body-weight regulation through amylin-receptor signaling in the central nervous system and peripheral metabolic pathways. Zealand Pharma describes petrelintide as a long-acting amylin analog designed to increase satiety and potentially improve leptin sensitivity. Because its primary mechanism differs from GLP-1 receptor agonists, it may be studied alone or in future combinations with incretin therapies.
Current research status
As of June 1, 2026, petrelintide is in Phase 2 development, with Phase 3 planned after completion and review of the ZUPREME program. Zealand Pharma reports Phase 2 ZUPREME-1 and ZUPREME-2 programs, while ClinicalTrials.gov lists ZUPREME-1 as a completed randomized, double-blind, placebo-controlled, dose-finding Phase 2 study in adults with obesity or overweight with weight-related comorbidities.
Potential benefits
- A non-GLP-1 satiety mechanism that may diversify obesity-treatment options.
- Potential body-weight reduction through amylin-receptor signaling and appetite regulation.
- Once-weekly administration under investigation.
- Potential future use as monotherapy or in combinations with incretin-based therapies if trials support safety and efficacy.
Safety and side effects
Petrelintide remains investigational. Early summaries from Zealand Pharma describe Phase 1b treatment as generally well tolerated and report no serious or severe adverse events in that early program, but larger Phase 2 and Phase 3 datasets are needed. Potential adverse effects for amylin-pathway therapies may include nausea, vomiting, appetite reduction, injection-site reactions, and tolerability issues related to delayed gastric emptying or satiety pathways.
Quick facts
| Research sponsor | Zealand Pharma |
|---|---|
| Primary target | Amylin receptors |
| Development stage | Phase 2 |
| Typical study route | Once-weekly subcutaneous injection |
| Regulatory status | Investigational; not FDA-approved |
Related reading
Read the June 1, 2026 blog article about next-generation weight-loss peptides beyond GLP-1.
References
Educational note
Peptide Science 101 is for education only and does not provide diagnosis, treatment, prescribing guidance, or individualized medical advice. Investigational peptides should only be used within properly regulated research or clinical-trial settings.